RxDoctor Payments Data

Randall Williams, MD

General Practice · Chico, CANPI 1245261114

Payments from drug & device makers

$34,490in general payments, 2019–2025

Across 2,023 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$6K
  • AbbVie$5K
  • Novo Nordisk$3K
  • Pfizer$2K
  • AstraZeneca$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$3,2409%
  • Food & beverage$31,14490%
  • Education$1060%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen168$6,288
AbbVie(2 entities)323$5,244
Novo Nordisk157$2,829
Pfizer177$2,015
AstraZeneca65$1,849
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC131$1,638
Lilly USA, LLC103$1,240
Johnson & Johnson(2 entities)102$1,080
Boehringer Ingelheim65$987
Corcept Therapeutics47$974
GSK63$927
Merck59$877
Daiichi Sankyo Inc.40$772
Amarin Pharma, Inc.59$689
Esperion Therapeutics, Inc.24$407
Biohaven Pharmaceutical Holding Company Ltd.38$396
Exact Sciences22$380
Takeda Pharmaceuticals U.S.A., Inc.23$326
Bayer21$320
Abbott14$305
Biohaven Pharmaceuticals, Inc.32$288
Sanofi-aventis U.S. LLC24$278
Astellas Pharma US Inc15$258
Madrigal Pharmaceuticals5$256
Eisai Inc.21$252
Sanofi Pasteur Inc.13$212
Dexcom, Inc.8$165
Pacira Therapeutics, Inc.13$160
E.r. Squibb & Sons, L.L.C.10$157
Arbor Pharmaceuticals, Inc.12$154
Kowa Pharmaceuticals America, Inc.11$146
Idorsia Pharmaceuticals US Inc16$146
Teva Pharmaceuticals USA, Inc.8$140
Phathom Pharmaceuticals, Inc.9$127
Mylan Specialty L.p.7$124
Novartis6$123
Vertex4$112
Indivior Inc.4$106
Sumitomo Pharma America, Inc.6$105
Pacira Pharmaceuticals Incorporated5$101
Sunovion Pharmaceuticals Inc.12$99
Upsher-smith Laboratories LLC4$96
Otsuka America Pharmaceutical, Inc.4$95
Axsome Therapeutics, Inc.4$93
Verity Pharmaceuticals Inc.5$86
Seqirus USA Inc4$75
Mannkind Corporation4$71
Aimmune Therapeutics, Inc.4$71
Optinose US, Inc.3$59
Scilex Pharmaceuticals Inc.3$53
Adlon Therapeutics L.p.3$52
Ironwood Pharmaceuticals, Inc3$51
Boston Scientific2$42
Bausch Health US, LLC3$40
Radius Health, Inc.2$37
Medtronic(2 entities)2$37
Tandem Diabetes Care, Inc.2$36
Fidia Pharma USA Inc.3$34
Fresenius Kabi USA, LLC1$32
Avanir Pharmaceuticals, Inc.2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,490 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$1,641,802
Medicare patients
1,534
Services billed
71,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide585$622,851
OzempicSemaglutide197$263,364
EliquisApixaban198$179,065
ArexvyRsvpref3 Antigen/As01e/Pf365$114,052
FarxigaDapagliflozin Propanediol48$53,430
JardianceEmpagliflozin41$44,464
MyrbetriqMirabegron43$39,975
XareltoRivaroxaban20$32,666
Repatha SureclickEvolocumab31$31,730
Rosuvastatin Calcium1,563$27,608
BelsomraSuvorexant59$26,466
TrulicityDulaglutide24$22,525
LinzessLinaclotide30$21,987
ShingrixVaricella-Zoster Ge/As01b/Pf93$20,589
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$18,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,240$645,376609 claims
Novo NordiskOzempic$2,829$263,364197 claims
GSKArexvy, Shingrix, Anoro Ellipta, Trelegy Ellipta, Breo Ellipta$927$182,285507 claims
PfizerEliquis$2,015$179,065198 claims
Boehringer IngelheimJardiance, Glyxambi$987$62,31053 claims
AstraZenecaFarxiga$1,849$53,43048 claims
MerckBelsomra, Janumet Xr, Dulera$877$47,99282 claims
AbbVieLinzess, Creon, Synthroid$5,244$42,422120 claims
Astellas Pharma US IncMyrbetriq$258$39,97543 claims
Johnson & JohnsonXarelto$1,080$32,66620 claims
Sumitomo Pharma America, Inc.Gemtesa$105$16,74621 claims
NovartisEntresto$123$12,55515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →